Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Helicobacter pylori exposure reduces eosinophilic esophagitis risk

03 Feb 2019

Exposure to Helicobacter pylori appears to lower the risk of eosinophilic oesophagitis (EoE), according to a study. 

Researchers searched four large databases for comparative clinical studies with sufficient data to estimate the odds or risk of EoE (primary outcome) or oesophageal eosinophilia (secondary outcome) among individuals exposed to H. pylori (exposed) vs those who were tested negatively.

The meta-analysis included 11 observational studies involving 377,795 individuals worldwide. Data were pooled using random-effects model. Meta-regression and sensitivity analyses were planned a priori. Studies were individually assessed for quality, risk of bias, publication bias and heterogeneity.

Estimates showed that compared with nonexposure, H. pylori exposure was associated with a >30-percent decrease in the odds of EoE (odds ratio [OR], 0.63; 95 percent CI, 0.51–0.78) and of oesophageal eosinophilia (OR, 0.62; 0.52–0.76).

There were fewer prospective vs retrospective studies that reported a significant relationship between H. pylori exposure and EoE (p=0.06). Effect estimates were not altered by study location, whether the studies were conducted in paediatric or adult populations, time period (before vs after 2007), or prevalence of H. pylori in the study population.

Evidence has reported that previous or current infection with H. pylori protects against EoE, potentially due to infection-induced immunomodulation, researchers said. The present data lend support to this evidence, although more research is needed to determine the mechanisms of such a benefit.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.